JP2002080355A - Preventing and treating agent for hypertension - Google Patents
Preventing and treating agent for hypertensionInfo
- Publication number
- JP2002080355A JP2002080355A JP2000268100A JP2000268100A JP2002080355A JP 2002080355 A JP2002080355 A JP 2002080355A JP 2000268100 A JP2000268100 A JP 2000268100A JP 2000268100 A JP2000268100 A JP 2000268100A JP 2002080355 A JP2002080355 A JP 2002080355A
- Authority
- JP
- Japan
- Prior art keywords
- hypertension
- acid
- preventing
- blood pressure
- ferulic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Non-Alcoholic Beverages (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、高血圧症予防・治
療剤に関する。TECHNICAL FIELD The present invention relates to an agent for preventing and treating hypertension.
【0002】[0002]
【従来の技術】狭心症、心筋梗塞、心不全などの心疾患
あるいは脳梗塞、脳出血、クモ膜下出血などの脳血管疾
患は、高血圧と非常に深い関係があり、日本人の死因の
それぞれ第二位と第三位を占める。また、厚生省国民生
活基礎調査(平成10年度)によれば、高血圧症で通院
する患者数は我が国で千人あたり64人であり、病因の
第一位を占めている。高血圧の対策としては、利尿薬、
交感神経抑制薬、血管拡張薬、アンジオテンシン交換酵
素阻害薬などの血圧降下医薬品が挙げられ、これらは主
として重症高血圧患者に適用される。それに対して、食
事療法、運動療法、飲酒・喫煙の制限などの生活習慣改
善を目的とした一般療法は、軽症者から重症者までの高
血圧者に広く適用されることから、一般療法の重要性が
認識されている。なかでも食習慣の改善は重要であると
いわれ、伝承として血圧降下作用を有すると言われる食
品は数多く存在する。また従来から食品由来の血圧降下
素材の探索が盛んに行われ、血圧降下作用を有する有効
成分の分離・同定が数多くなされている。2. Description of the Related Art Heart diseases such as angina pectoris, myocardial infarction, and heart failure or cerebrovascular diseases such as cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage are very closely related to hypertension. Occupies second and third place. According to the Ministry of Health and Welfare Basic Survey on Human Life (1998), the number of patients who visit the hospital for hypertension is 64 per 1,000 in Japan, which is the leading cause of the disease. As measures against hypertension, diuretics,
Antihypertensive drugs, such as sympathomimetic drugs, vasodilators, and angiotensin exchange enzyme inhibitors, are mainly applied to patients with severe hypertension. On the other hand, general therapies aimed at improving lifestyle, such as diet, exercise, and restricting drinking and smoking, are widely applied to hypertensive patients from mild to severe. Is recognized. Above all, it is said that improving eating habits is important, and there are many foods that are said to have a blood pressure lowering effect as a tradition. In addition, search for food-derived blood pressure lowering materials has been actively conducted, and many active ingredients having blood pressure lowering action have been separated and identified.
【0003】[0003]
【発明が解決しようとする課題】しかし、現状において
高血圧症対策の目的で使用される医薬品は、有効性に関
しては満足できるものが多い反面、少なからず存在する
頻脈・徐脈等の副作用のため患者にかかる負担が大き
い。また、血圧降下作用を有するといわれる食品あるい
はその有効成分に関しても、その有効性には必ずしも満
足できるものではなく、また血圧降下効果が発現される
までに長期間を要するものが多い。However, many of the pharmaceuticals currently used for the purpose of countermeasures against hypertension are satisfactory in terms of efficacy, but because of the side effects such as tachycardia and bradycardia which are not a little present. The burden on the patient is great. In addition, foods that are said to have a blood pressure lowering action or active ingredients thereof are not always satisfactory in their effectiveness, and many require a long period of time to develop a blood pressure lowering effect.
【0004】従って、本発明の目的は、日常食用できる
安全性に優れ、日常的な摂取にも負担にならず、且つよ
り高い抗高血圧作用を有する飲食品、特定保健用食品、
医薬部外品及び医薬品を提供することにある。[0004] Accordingly, an object of the present invention is to provide a food and drink, a food for specified health use, and the like, which are excellent in safety for daily consumption, do not burden daily intake, and have a higher antihypertensive effect.
An object of the present invention is to provide quasi-drugs and pharmaceuticals.
【0005】[0005]
【課題を解決するための手段】本発明は、(a)カフェ
酸、クロロゲン酸、フェルラ酸、それらのエステル及び
それらの薬学的に許容される塩からなる群から選ばれる
化合物と、(b)糖アルコールを含有する、高血圧症の
予防・治療剤を提供するものである。According to the present invention, there is provided a compound selected from the group consisting of (a) caffeic acid, chlorogenic acid, ferulic acid, esters thereof and pharmaceutically acceptable salts thereof, and (b) It is intended to provide a prophylactic / therapeutic agent for hypertension containing a sugar alcohol.
【0006】[0006]
【発明の実施の形態】本発明で用いる成分(a)はこれ
を含有する天然物(特に植物)の抽出物を用いることがで
きる。植物としては、例えば、コーヒー、タマネギ、ダ
イコン、レモン、モロヘイヤ、センキュウ、トウキ、マ
ツ、オウレン、アギ、カンショ、トウモロコシ、大麦、
コメ等が挙げられる。BEST MODE FOR CARRYING OUT THE INVENTION As the component (a) used in the present invention, an extract of a natural product (particularly, a plant) containing the same can be used. Plants include, for example, coffee, onion, radish, lemon, moloheiya, senkyu, touki, pine, spinach, agi, sweet potato, corn, barley,
Rice and the like.
【0007】カフェ酸、クロロゲン酸としては、コーヒ
ー生豆、南天の葉、リンゴ未熟果等の植物から抽出した
ものでもよく、例えばアカネ科コーヒー(Coffea arabic
a LINNE)の種子より、温時アスコルビン酸、クエン酸酸
性水溶液又は熱水で抽出して得られたものが好ましい。The caffeic acid and chlorogenic acid may be those extracted from plants such as green coffee beans, leaves of southern sky, immature apples, and the like. For example, coffee of the family Rubiaceae (Coffea arabic)
a LINNE) is preferably obtained by extraction with hot ascorbic acid, aqueous citric acid solution or hot water from seeds of LINNE).
【0008】本発明で用いるフェルラ酸は、そのエステ
ル体がコメあるいはハトムギ等の天然物、特に植物に含
まれる化合物であり、植物からの精製物あるいは工業的
に得られる合成品として得ることができる。フェルラ酸
エステルは、例えば、コメの糠より得られた米糠油を、
室温時弱アルカリ性下で含水エタノール及びヘキサンで
分配した後、含水エタノール画分に得られる。フェルラ
酸は、上記工程より得られたフェルラ酸エステルを加圧
加熱下硫酸で加水分解し、精製して得るか、又は細菌(P
seudomonas)を、フトモモ科チョウジノキ(Syzygium ar
omaticum MERRILL et PERRY)のつぼみ及び葉より水蒸
気蒸留で得られた丁子油、又は丁子油から精製して得ら
れたオイゲノールを含む培養液で培養し、その培養液
を、分離、精製して得ることができる。The ferulic acid used in the present invention is a natural product such as rice or barley, particularly a compound contained in plants, and can be obtained as a purified product from plants or a synthetic product obtained industrially. . Ferulic acid ester, for example, rice bran oil obtained from rice bran,
After partitioning with aqueous ethanol and hexane at room temperature under weak alkalinity, the aqueous ethanol fraction is obtained. Ferulic acid can be obtained by hydrolyzing the ferulic acid ester obtained in the above step with sulfuric acid under pressure and heat and purifying it, or by obtaining bacteria (P
seudomonas) in the family Myrtaceae (Syzygium ar
omaticum MERRILL et PERRY) from buds and leaves of steam-distilled clove oil or a culture solution containing eugenol obtained by refining clove oil, and separating and purifying the culture solution. Can be.
【0009】化学合成によってフェルラ酸を調製する場
合は、例えば、バニリンとマロン酸との縮合反応によっ
て製造することができる(Journal of American Chemic
al Society,74,5346,1952)。なお、カフェ酸、クロロ
ゲン酸、フェルラ酸又はそれらの製剤学的に許容される
塩には、立体異性体が存在し、本発明では、純粋な立体
異性体又はそれらの混合物を用いることができる。When ferulic acid is prepared by chemical synthesis, it can be produced, for example, by a condensation reaction between vanillin and malonic acid (Journal of American Chemic).
al Society, 74, 5346, 1952). In addition, caffeic acid, chlorogenic acid, ferulic acid, or a pharmaceutically acceptable salt thereof has a stereoisomer, and in the present invention, a pure stereoisomer or a mixture thereof can be used.
【0010】カフェ酸、クロロゲン酸又はフェルラ酸の
エステル体は、天然物、特に植物中に本来含有されてい
るもの、抽出又は分画の際の化学的処理によって変換し
たもの及び化学的修飾を行ったものなどが含まれる。具
体的には、例えば、フェルラ酸エステル等を挙げること
ができる。フェルラ酸エステルの具体例としては、例え
ば、炭素数1〜40のアルコールとのエステルであり、
直鎖状若しくは分岐状のアルキル若しくはアルケニルア
ルコール、アリルアルコール、テルペンアルコール、ス
テロール、又はトリメチルステロールと、フェルラ酸と
のエステル化合物が挙げられる。本発明には上述のこれ
らフェルラ酸エステルのフェルラ酸をカフェ酸あるいは
クロロゲン酸で置き換えたものも含まれる。Esters of caffeic acid, chlorogenic acid or ferulic acid are natural products, especially those originally contained in plants, those converted by chemical treatment upon extraction or fractionation, and those subjected to chemical modification. And others are included. Specific examples include ferulic acid esters. Specific examples of the ferulic acid ester include, for example, an ester with an alcohol having 1 to 40 carbon atoms,
An ester compound of linear or branched alkyl or alkenyl alcohol, allyl alcohol, terpene alcohol, sterol, or trimethyl sterol with ferulic acid may be mentioned. The present invention also includes those obtained by replacing ferulic acid in these ferulic acid esters with caffeic acid or chlorogenic acid.
【0011】カフェ酸、クロロゲン酸、フェルラ酸を薬
学的に許容される塩の形で用いることにより水溶性が向
上し、生理学的有効性が増大する。これら薬学的に許容
される塩の塩形成用の塩基物質としては、例えば、アル
カリ金属あるいはアルカリ土類金属の水酸化物、例え
ば、水酸化リチウム、水酸化ナトリウム、水酸化カリウ
ム、水酸化マグネシウム、水酸化カルシウム、又は水酸
化アンモニウム等の無機塩基、アルギニン、リジン、ヒ
スチジン、オルニチン等の塩基性アミノ酸、又はモノエ
タノールアミン、ジエタノールアミン、トリエタノール
アミン等の有機塩基が用いられるが、特に好ましいもの
として、アルカリ金属あるいはアルカリ土類金属の水酸
化物が挙げられる。これらの塩を調製してから、その塩
を本発明品中に添加してもよいし、塩形成成分を本発明
品中に別々に添加して処方系中で反応させてもよい。The use of caffeic, chlorogenic and ferulic acids in the form of pharmaceutically acceptable salts improves water solubility and increases physiological effectiveness. Examples of the base substance for salt formation of these pharmaceutically acceptable salts include hydroxides of alkali metals or alkaline earth metals, for example, lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, Inorganic bases such as calcium hydroxide or ammonium hydroxide, arginine, lysine, histidine, basic amino acids such as ornithine, or monoethanolamine, diethanolamine, organic bases such as triethanolamine are used. Alkali metal or alkaline earth metal hydroxides may be mentioned. After preparing these salts, the salts may be added to the product of the present invention, or the salt-forming components may be separately added to the product of the present invention and reacted in a formulation system.
【0012】成分(a)は、2種以上を併用してもよ
い。As the component (a), two or more kinds may be used in combination.
【0013】本発明で用いる成分(b)糖アルコール
は、天然物、特に植物中に本来含有されているもの、抽
出又は分画の際の化学的処理によって変換したもの、及
び化学的修飾を行ったものなどが含まれる。具体的に
は、単糖類、オリゴ糖類、多糖類等のカルボニル基を還
元して、アルコールに変えたものが用いられ、単糖アル
コールの具体例としてブドウ糖を酵母で発酵分解して選
ばれる4炭糖の糖アルコールであるエリスリトールや、
5炭糖のキシリトール、6炭糖のソルビトール、マンニ
トール等が、オリゴ糖類の具体例として2糖アルコール
のパラチニット(還元パラチノース)、マルチトール
(還元麦芽糖)、ラクチトール、分岐オリゴ糖アルコー
ル等が、多糖アルコールの具体例として、還元水飴とし
て利用されている還元デキストリン等が挙げられる。The component (b) sugar alcohol used in the present invention is a natural product, especially one originally contained in a plant, one converted by a chemical treatment at the time of extraction or fractionation, and subjected to chemical modification. And others are included. Specifically, monosaccharides, oligosaccharides, polysaccharides, and the like, in which the carbonyl group is reduced to alcohol are used. As a specific example of the monosaccharide alcohol, glucose is selected by fermenting and decomposing glucose with yeast. Erythritol, a sugar alcohol of sugar,
Pentose xylitol, hexose sorbitol, mannitol and the like are specific examples of oligosaccharides. Disaccharide alcohol palatinit (reduced palatinose), maltitol (reduced maltose), lactitol, branched oligosaccharide alcohols and the like are polysaccharide alcohols. Specific examples include reduced dextrin used as reduced starch syrup and the like.
【0014】成分(b)のうち、エリスリトール、キシ
リトール、マルチトール、パラチニット、還元デキスト
リン、分岐オリゴ糖アルコールが好ましいものとして挙
げられる。成分(b)は、2種以上を併用してもよい。Of the component (b), erythritol, xylitol, maltitol, palatinit, reduced dextrin, and branched oligosaccharide alcohol are preferred. As the component (b), two or more kinds may be used in combination.
【0015】本発明の高血圧症予防・治療剤を医薬とし
て用いる場合、上記有効成分に薬学的に許容される担体
を添加して、経口用又は非経口用の組成物とすることが
できる。経口用組成物としては、錠剤、顆粒剤、細粒
剤、丸剤、散剤、カプセル剤(硬カプセル剤及び軟カプ
セル剤を含む)、トローチ剤、チュアブル剤、液剤(ド
リンク剤)などが挙げられる。また、非経口用組成物と
しては、注射剤などの静脈内投与製剤、坐剤、皮膚外用
剤などが挙げられる。When the agent for preventing or treating hypertension of the present invention is used as a medicine, a pharmaceutically acceptable carrier can be added to the above-mentioned active ingredient to prepare an oral or parenteral composition. Examples of the oral composition include tablets, granules, fine granules, pills, powders, capsules (including hard capsules and soft capsules), troches, chewables, and liquids (drinks). . Examples of the parenteral composition include intravenous preparations such as injections, suppositories, and external preparations for skin.
【0016】本発明の高血圧症予防・治療剤を食品とし
て用いる場合、飲料、スープ等の液状食品、牛乳、カレ
ー等の乳状又はペースト状食品、ゼリー、グミ、ジャム
等の半固形状食品、ガム、豆腐等の固形状食品、あるい
は粉末状食品、マーガリン、マヨネーズ、ドレッシング
等の油脂含有食品、砂糖代替調味料等いかなる形態でも
よい。When the agent for preventing or treating hypertension of the present invention is used as a food, liquid foods such as drinks and soups, milky or pasty foods such as milk and curry, semi-solid foods such as jelly, gummy and jam, gums , Solid foods such as tofu, powdered foods, foods containing fats and oils such as margarine, mayonnaise, and dressings, and alternative forms of sugar substitutes.
【0017】製剤中における成分(a)の含有量として
は、0.005〜5重量%(以下単に%と記載する)、
好ましくは0.01〜1%、成分(b)としては、0.
1〜70%、好ましくは1〜50%である。The content of the component (a) in the preparation is 0.005 to 5% by weight (hereinafter simply referred to as%),
Preferably, it is 0.01 to 1%, and the component (b) is 0.1 to 1%.
It is 1-70%, preferably 1-50%.
【0018】本発明に用いる成分(a)の成人(体重6
0kg)1日あたりの有効投与量は、1日に0.001〜
10g、特に0.005〜5gを摂取するようなもので
あることが好ましい。また、成分(b)の成人(体重6
0kg)1日あたりの有効投与量は、1日に0.1〜50
g、特に1〜20gを摂取するようなものであることが
好ましい。An adult (body weight 6) of the component (a) used in the present invention.
0kg) The effective daily dose is 0.001 to
Preferably, it is such that it consumes 10 g, especially 0.005 to 5 g. In addition, an adult (body weight 6) of the component (b)
0 kg) The effective daily dose is 0.1 to 50
g, especially 1-20 g.
【0019】[0019]
【実施例】実施例1 ラットにおける血圧上昇抑制評価 (1)使用動物 7週齢の雄性自然発症高血圧ラット(SHR)を、予備
的に7日間連続で市販のラット用非観式血圧測定装置
(ソフトロン社製)を用いて血圧測定することにより、
ラットを血圧測定操作に十分慣れさせたのち、評価試験
を開始した。ラットはすべて温度25±1℃、相対湿度
55±10%、照明時間12時間(午前7時〜午後7
時)の条件下(ラット区域内飼育室)で飼育した。Example 1 Evaluation of Suppression of Elevated Blood Pressure in Rats (1) Animal used Seven-week-old male spontaneously hypertensive rats (SHR) were prepared for 7 consecutive days in advance using a commercially available non-invasive blood pressure measuring device for rats ( By measuring blood pressure using Softlon Co., Ltd.)
After the rats were sufficiently familiarized with the blood pressure measurement operation, an evaluation test was started. All rats had a temperature of 25 ± 1 ° C., a relative humidity of 55 ± 10%, and an illumination time of 12 hours (7:00 am to 7 pm)
H) (bred room in the rat area).
【0020】(2)投与方法及び投与量 対照区では、1%の砂糖水溶液を飲料水とし、市販の固
形飼料を自由摂取させた。試験区1では0.1%フェル
ラ酸(和光純薬(株)製)と1%砂糖を含む水溶液を飲
料水とし、市販の固形飼料を自由摂取させた。試験区2
(本発明)では0.1%フェルラ酸と1%エリスリトー
ル(和光純薬(株)製)とを含む水溶液を飲料水とし市
販の固形飼料を自由摂取させた。(2) Administration method and dosage In the control group, a 1% aqueous sugar solution was used as drinking water, and a commercially available solid feed was freely ingested. In test plot 1, an aqueous solution containing 0.1% ferulic acid (manufactured by Wako Pure Chemical Industries, Ltd.) and 1% sugar was used as drinking water, and a commercially available solid feed was freely ingested. Test plot 2
In the present invention, an aqueous solution containing 0.1% ferulic acid and 1% erythritol (manufactured by Wako Pure Chemical Industries, Ltd.) was used as drinking water, and a commercially available solid feed was freely ingested.
【0021】(3)試験方法 SHRを1群8匹で使用し、4週間後、尾動脈の収縮期
血圧を測定した。(3) Test method SHR was used in 8 animals per group, and after 4 weeks, systolic blood pressure of the tail artery was measured.
【0022】(4)統計学的処理方法 得られた試験成績は平均値及び標準誤差で表してStuden
t's t-testを行い、有意水準は5%以下とした。(4) Statistical processing method The obtained test results are expressed as an average value and a standard error.
A t's t-test was performed and the significance level was set to 5% or less.
【0023】表1に、投与開始前及び投与4週間後にお
ける収縮期血圧を示した。表1から明らかなように、試
験区2の本発明品の摂取により、顕著な血圧上昇抑制作
用を認めた。Table 1 shows the systolic blood pressure before administration and 4 weeks after administration. As is clear from Table 1, the ingestion of the product of the present invention in Test Section 2 showed a remarkable blood pressure increase suppressing effect.
【0024】[0024]
【表1】 [Table 1]
【0025】実施例2 ラットにおける降圧評価 (1)使用動物 14週齢の雄性自然発症高血圧ラット(SHR)を実施
例1と同様に予備飼育した。 (2)投与方法及び投与量 対照区では、1%の砂糖水溶液を経口投与した。試験区
1では0.2%フェルラ酸と1%砂糖を含む水溶液を経
口投与した。試験区2では0.2%フェルラ酸と1%エ
リスリトールとを含む水溶液を経口投与した。投与量は
15mL/kgとした。 (c)試験方法 SHRを1群6匹で使用し、投与後1時間目の尾動脈収
縮期血圧を測定した。Example 2 Evaluation of Hypotension in Rats (1) Animals Used Male 14-week-old male spontaneously hypertensive rats (SHR) were preliminarily bred in the same manner as in Example 1. (2) Administration method and dosage In the control group, a 1% aqueous solution of sugar was orally administered. In test group 1, an aqueous solution containing 0.2% ferulic acid and 1% sugar was orally administered. In Test Group 2, an aqueous solution containing 0.2% ferulic acid and 1% erythritol was orally administered. The dose was 15 mL / kg. (C) Test method Six SHRs were used per group, and the systolic blood pressure of the tail artery 1 hour after administration was measured.
【0026】表2に、実施例1と同様に統計学的処理し
た投与開始前及び投与1時間後における収縮期血圧を示
した。表2から明らかなように、該組成物の摂取により
顕著な血圧の降下を認めた。Table 2 shows the systolic blood pressure before administration and 1 hour after administration, which were statistically treated in the same manner as in Example 1. As is evident from Table 2, a significant decrease in blood pressure was observed upon ingestion of the composition.
【0027】[0027]
【表2】 [Table 2]
【0028】実施例3 軟カプセル剤 軟カプセル剤皮(オバール型、重さ150mg)の中にク
ロロゲン酸(和光純薬(株)製)50mgとマルチトール
(和光純薬(株)製)450mgを定法により充填し、軟
カプセル剤を製造した。良好な血圧降下作用を示した。Example 3 Soft Capsules 50 mg of chlorogenic acid (manufactured by Wako Pure Chemical Industries, Ltd.) and 450 mg of maltitol (manufactured by Wako Pure Chemical Industries, Ltd.) were placed in a soft capsule skin (oval type, weight 150 mg). Filling was performed by a conventional method to produce a soft capsule. It showed a good blood pressure lowering effect.
【0029】 実施例4 飲料 脱脂粉乳 3.5 % レモンエキス 3.5 パラチニット(和光純薬(株)製) 9.0 フェルラ酸ナトリウム(和光純薬(株)製) 0.1 クエン酸 0.1 アスコルビン酸 0.1 香料 0.1 水 83.6 上記組成の飲料の保存安定性は高く、また、風味も良好
であった。Example 4 Beverage Skim Milk Powder 3.5% Lemon Extract 3.5 Palatinit (Wako Pure Chemical Industries, Ltd.) 9.0 Sodium Ferulate (Wako Pure Chemical Industries, Ltd.) 0.1 Citric Acid 1 Ascorbic acid 0.1 Flavor 0.1 Water 83.6 The storage stability of the beverage having the above composition was high, and the flavor was also good.
【0030】 実施例5 クッキー 菜種油 12 % コーンスターチ 12 オレンジエキス 5 小麦粉 40 バター 5 還元デキストリン(和光純薬(株)製) 14 フェルラ酸シクロアルテノール(和光純薬(株)製) 1 食塩 0.5 重曹 0.5 水 10 上記組成から成るクッキーを焼成した。美味であった。Example 5 Cookies Rapeseed oil 12% Corn starch 12 Orange extract 5 Flour 40 Butter 5 Reduced dextrin (manufactured by Wako Pure Chemical Industries, Ltd.) 14 Cycloartenol ferulate (manufactured by Wako Pure Chemical Industries, Ltd.) 1 Salt 0.5 Baking soda 0.5 water 10 A cookie having the above composition was baked. It was delicious.
【0031】[0031]
【発明の効果】血圧の上昇が抑制されるとともに、高血
圧症が改善され、高血圧症予防・治療用の医薬品及び食
品として用いることができる。EFFECT OF THE INVENTION The increase in blood pressure is suppressed and hypertension is improved, so that it can be used as a medicament and food for preventing and treating hypertension.
フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A23L 1/30 A23L 1/30 Z 4C206 2/52 C07H 13/04 C07H 13/04 A23L 2/00 F (72)発明者 時光 一郎 栃木県芳賀郡市貝町赤羽2606 花王株式会 社研究所内 Fターム(参考) 4B017 LC03 LK06 LK12 LL09 4B018 LB01 LB08 MD09 MD10 MD32 ME04 4B032 DB21 DK07 DK12 DL20 4C057 HH02 4C086 AA01 AA02 EA03 MA02 MA05 NA14 ZA42 4C206 AA01 AA02 DA21 DB20 DB41 MA02 MA03 MA05 NA14 ZA42Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat II (Reference) A23L 1/30 A23L 1/30 Z 4C206 2/52 C07H 13/04 C07H 13/04 A23L 2/00 F (72) Invention Person Ichiro Tokitsu 2606 Akabane, Kakaicho, Haga-gun, Tochigi Prefecture F-term in the Kao Corporation Research Laboratories (reference) 4B017 LC03 LK06 LK12 LL09 4B018 LB01 LB08 MD09 MD10 MD32 ME04 4B032 DB21 DK07 DK12 DL20 4C057 HH02 4C086 AA03 MA02A42A14 AA01 AA02 DA21 DB20 DB41 MA02 MA03 MA05 NA14 ZA42
Claims (1)
ラ酸、それらのエステル及びそれらの薬学的に許容され
る塩からなる群から選ばれる化合物と、(b)糖アルコ
ールとを含有する高血圧症予防・治療剤。1. Hypertension comprising (a) a compound selected from the group consisting of caffeic acid, chlorogenic acid, ferulic acid, esters thereof and pharmaceutically acceptable salts thereof, and (b) a sugar alcohol. Prophylactic and therapeutic agents.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000268100A JP4520602B2 (en) | 2000-09-05 | 2000-09-05 | Antihypertensive agent |
US09/944,079 US6991812B2 (en) | 2000-09-05 | 2001-09-04 | Agent for preventing, improving or treating hypertension |
EP06022311A EP1757324A3 (en) | 2000-09-05 | 2001-09-05 | Agent for preventing, improving or treating hypertension |
EP01121289A EP1186297A3 (en) | 2000-09-05 | 2001-09-05 | Agent for preventing, improving or treating hypertension |
US10/626,708 US7351436B2 (en) | 2000-09-05 | 2003-07-25 | Agent for preventing, improving or treating hypertension |
US11/209,672 US20050281897A1 (en) | 2000-09-05 | 2005-08-24 | Agent for preventing, improving or treating hypertension |
US11/452,374 US20060233897A1 (en) | 2000-09-05 | 2006-06-14 | Agent for preventing, improving or treating hypertension |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000268100A JP4520602B2 (en) | 2000-09-05 | 2000-09-05 | Antihypertensive agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002080355A true JP2002080355A (en) | 2002-03-19 |
JP4520602B2 JP4520602B2 (en) | 2010-08-11 |
Family
ID=18754916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000268100A Expired - Fee Related JP4520602B2 (en) | 2000-09-05 | 2000-09-05 | Antihypertensive agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4520602B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004528050A (en) * | 2001-06-13 | 2004-09-16 | ジボダン エス エー | Taste modifier containing chlorogenic acid |
CN109876135A (en) * | 2019-04-25 | 2019-06-14 | 陈东良 | It is a kind of can reducing blood pressure and blood fat folium cortex eucommiae corn peptide combinations and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04243822A (en) * | 1991-01-24 | 1992-08-31 | Tsumura & Co | Calcium antagonist |
JPH07285876A (en) * | 1993-12-06 | 1995-10-31 | Nikka Uisukii Kk | Fruit polyphenol, its production, antioxidant, antihypertensive agent, anti-mutagenicity agent, allergy inhibitor, cariostatic agent and deodorant |
CN1192357A (en) * | 1998-03-04 | 1998-09-09 | 中国人民解放军空军总医院科技开发部 | New use of caffeic acid and ferulic acid antagonistic endotheliolysin biological effect |
JPH1143429A (en) * | 1997-05-27 | 1999-02-16 | Takeda Chem Ind Ltd | Solid preparation |
-
2000
- 2000-09-05 JP JP2000268100A patent/JP4520602B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04243822A (en) * | 1991-01-24 | 1992-08-31 | Tsumura & Co | Calcium antagonist |
JPH07285876A (en) * | 1993-12-06 | 1995-10-31 | Nikka Uisukii Kk | Fruit polyphenol, its production, antioxidant, antihypertensive agent, anti-mutagenicity agent, allergy inhibitor, cariostatic agent and deodorant |
JPH1143429A (en) * | 1997-05-27 | 1999-02-16 | Takeda Chem Ind Ltd | Solid preparation |
CN1192357A (en) * | 1998-03-04 | 1998-09-09 | 中国人民解放军空军总医院科技开发部 | New use of caffeic acid and ferulic acid antagonistic endotheliolysin biological effect |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004528050A (en) * | 2001-06-13 | 2004-09-16 | ジボダン エス エー | Taste modifier containing chlorogenic acid |
US8197875B2 (en) | 2001-06-13 | 2012-06-12 | Givaudan Sa | Taste modifiers comprising a chlorogenic acid |
US10597620B2 (en) | 2001-06-13 | 2020-03-24 | Givaudan Sa | Taste modifiers comprising a chlorogenic acid |
CN109876135A (en) * | 2019-04-25 | 2019-06-14 | 陈东良 | It is a kind of can reducing blood pressure and blood fat folium cortex eucommiae corn peptide combinations and preparation method thereof |
CN109876135B (en) * | 2019-04-25 | 2022-09-06 | 陈东良 | Eucommia ulmoides leaf and corn peptide composition capable of reducing blood pressure and blood fat and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP4520602B2 (en) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3548102B2 (en) | Antihypertensive agent | |
US6991812B2 (en) | Agent for preventing, improving or treating hypertension | |
JP2002154977A (en) | Composition for drinking and eating | |
JP4077149B2 (en) | Autonomic nervous function improver | |
JP4002654B2 (en) | Blood lipid improving agent, cyclic AMP phosphodiesterase inhibitor, obesity preventive / eliminating agent, food and beverage, and skin external preparation | |
JP4119629B2 (en) | Antihypertensive agent | |
WO2007066642A1 (en) | Oral preparation for preventing or improving skin dryness | |
JP2002087977A (en) | Prophylactic, improving and therapeutic agent for hypertension | |
EP1090635B1 (en) | Use of ferulic acid for treating hypertension | |
JPH10265397A (en) | Agent for preventing obesity | |
JP2003261444A (en) | Hemangioendothelial function improving agent | |
JP2004137287A (en) | Prophylactic/therapeutic agent for hypertension | |
JP4234888B2 (en) | Antihypertensive agent | |
JP4641090B2 (en) | Antihypertensive agent | |
JP4520602B2 (en) | Antihypertensive agent | |
JP2004155700A (en) | Ameliorant for cerebrovascular disorder | |
JP4666736B2 (en) | Antihypertensive agent | |
JP6194192B2 (en) | Adiponectin production promoter | |
JPWO2005074961A1 (en) | Body fat regulator | |
CN109310661A (en) | Improving blood flow agent, queen bee paste composition and queen bee paste composition manufacturing method | |
JP3345650B2 (en) | Hypertension inhibitor | |
JPH11147828A (en) | Absorption inhibitor against cholesterol and lipid | |
JP2003192584A (en) | Composition for preventing and improving hypertension | |
JP2002080381A (en) | Prophylactic/ameliorative/therapeutic agent for hypertension | |
JP2005200389A (en) | Alfa-glucosidase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060803 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100216 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100419 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100518 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100521 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130528 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140528 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |